Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma.
Serum lactic dehydrogenase (S-LDH) was analysed at diagnosis in ninety-three patients with multiple myeloma. The patients were then followed up after a mean observation period of 39 months (SD 29). Serum lactic dehydrogenase was elevated in twenty-seven out of ninety-three patients and found to correlate with the serum concentrations of beta 2-microglobuline, creatinine, and thymidine kinase. In discriminant analysis of pretreatment S-LDH levels in relation to survival, the best discrimination level was 7.0 mukat 1(-1). Patients with values below 7 microkat 1(-1) ahd a median survival time of 45 months compared to 14 months for those with levels above 7 mukat 1(-1) (P less than 0.001). Serum lactic dehydrogenase at diagnosis, thus, has prognostic information in multiple myeloma.
D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D009101:Multiple Myeloma / Q000097:blood / Q000201:enzymology* / Q000276:immunology; D011379:Prognosis; D013937:Thymidine Kinase / Q000097:blood; D013997:Time Factors; D001613:beta 2-Microglobulin / Q000378:metabolism
D007136:Immunoglobulins; D001613:beta 2-Microglobulin; D007770:L-Lactate Dehydrogenase; D013937:Thymidine Kinase